|Bid||1,605.00 x 175400|
|Ask||1,640.00 x 417900|
|Day's Range||1,614.50 - 1,632.00|
|52 Week Range||1,446.50 - 1,745.56|
|PE Ratio (TTM)||47.36|
|Dividend & Yield||1.00 (4.66%)|
|1y Target Est||N/A|
GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.
Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.
Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million.